Log Out A facility of the medical technology company Becton, Dickinson and Company (BD) in Sparks, Md.
on June 21, 2014.(Photo: Kristoffer Tripplaar / Sipa, Sipa USA) Murray Hill, N.J.-based Bard's portfolio of products in vascular, urology and oncology adds to BD's wide-ranging offerings, including diagnostics, diabetes care, injection, anesthesia, pharmacy and laboratory automation.
"Combining with Bard will accelerate our ability to offer more comprehensive, clinically relevant solutions to customers and patients around the globe, creating a strong partner for healthcare providers who are increasingly focused on delivering better outcomes at a lower total cost," BD CEO and chairman Vince Forlenza said in a statement.
Altogether, the combined company is projecting annual revenue growth of 5% to 6% from the 2018 through 2020 fiscal years with earnings growth in the "mid-teens" in percentage uptick, according to an investor presentation.